Description
This session will review novel pharmacological agents and mechanisms of action recently approved or in late-stage development for schizophrenia. Learners will gain insights into efficacy, safety, and tolerability data, as well as practical considerations for incorporating these latest and evidence-based therapies into individualized treatment plans.
Learning Objectives
Identify new and emerging pharmacological agents for schizophrenia and describe their mechanisms of action.
Compare the efficacy and safety of novel treatments with existing antipsychotic medications you may use today.
Apply evidence-based considerations when deciding whether and how to incorporate new pharmacological options into clinical practice for your patients.
Discuss potential benefits and limitations of the use of these agents with patients
Outline
- Schizophrenia
- Dopamine as the Target
- Recently Approved Agents
- Total Symptoms
- Weight Gain /Tardive Dyskinesia
- Relapse Prevention
- Novel and Emerging Agents
- Total Symptoms
- Negative Symptoms
- Cognitive Symptoms
- Question and answer
Format
Live webinar
Target Audience
Psychiatrist, Physician (Non-Psychiatric), Nurse Practitioner, Psychiatric Technician, Pharmacist
Instructional Level
Intermediate, Advanced
Estimated Time to Complete
Estimated Duration: 1 hour
Program Release Date: November 4, 2025
Program End Date: November 4, 2025
Ongoing Interdisciplinary Discussion Board
After completing the course, engage with colleagues in the mental health field through the Webinar Roundtable Topics discussion board. This is an easy way to network and share ideas with other clinicians who participate in this webinar. Access through the discussion tab.
How to Earn Credit
After completing the evaluation, participants will have the opportunity to claim their hours of participation and download the appropriate certificate. Physicians may obtain an official CME certificate, other healthcare professionals may receive a CE certificate (as applicable), and all other attendees may generate a certificate of participation. Each certificate will reflect the event date and total hours earned.
Continuing Education Credit
In support of improving patient care, American Psychiatric Association (APA) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The APA designates this live event for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses/Nurse Practitioners
The American Psychiatric Association (APA) designates this activity for 1.00 Nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.
Pharmacists
This curriculum has been approved for 1.00 contact hours by the American Psychiatric Association. The American Psychiatric Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is UAN JA0000145-0000-25-025-L05-P. This learning activity is knowledge based. Your CE credits will be electronically submitted to NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Faculty and Planner Disclosures
The American Psychiatric Association adheres to the ACCME's Standards for Integrity and Independence in Accredited Medical Education. Any individuals in a position to control the content of a CME activity - including faculty, planners, reviewers, or others - are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty:
- Dr. Christoph U. Correll is a highly distinguished psychiatry professor and researcher, holding positions at both the Zucker School of Medicine in New York and Charité University Medicine in Berlin, where he chairs the Child and Adolescent Psychiatry department. He completed his medical studies in Germany and Scotland, followed by dual residencies in general and child and adolescent psychiatry at Zucker Hillside Hospital in New York. Dr. Correll's clinical and research focus is on the early identification and psychopharmacological management of youth and adults with severe mental illnesses like schizophrenia, bipolar disorder, and major depression. He has achieved global recognition for his work on psychotropic medications and the interface between physical and mental health, with a specific focus on clinical trials, epidemiology, and meta-analyses. His profound influence is evidenced by his publication of over 900 highly cited articles, and he has consistently been ranked as one of the world's top experts in numerous psychiatric and pharmacological topics. Dr. Correll has financial relationships with various pharmaceutical companies acting as a consultant, expert testimony, board member and grant supporter.
Program Planners:
- John Torous, MD, Beth Israel Deaconess Medical Center. Dr. Torous has no relevant financial relationships to disclose.
- Kathryn Hanley, APRN, Austin State Hospital. Ms. Hanley has no relevant financial relationships to disclose.
- Megan Ehret, PharmD, BCPP, University of Maryland, Baltimore. Dr. Ehret is a consultant for Saladex Biomedical LLC.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.
Technical Requirements
This internet-based CME activity is best experienced using any of the following:
The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
Internet Explorer 11+
This Web site requires JavaScript and session cookies to be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be Adobe Acrobat Reader, Microsoft PowerPoint, or Windows Media Player.
Optimal System Configuration:
Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
Internet Connection: 1 Mbps or higher
Minimum Requirements:
Windows PC:
Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video
For assistance: Contact educme@psych.org for questions about this activity
Contact support@smicaladviser.org for technical assistance